Who we are | Boehringer Ingelheim US
Who we are
With over 50 years of innovation in the U.S., Boehringer Ingelheim maintains numerous sites across the country, including research & development (R&D) and manufacturing facilities for our medicines. There are over 9,000 employees representing all 50 states.
Boehringer plans to invest approximately $20 billion between 2025 and 2030 in its human and animal health business in the U.S. Roughly two-thirds of this investment is earmarked for R&D, driving the discovery and development of novel therapies across U.S. sites. The remaining one-third is planned to bolster manufacturing capabilities, at both our owned facilities and through our manufacturing partners in several locations across the country.
As a top global pharmaceutical company that develops innovative therapies in areas of high unmet medical need for the patients and animals we serve, Boehringer consistently ranks among the top of its peers for investments in R&D. Boehringer has remained independent since the company’s founding in 1885, which provides the freedom to take a long-term approach in achieving breakthroughs that transform patients’ lives. We believe that ensuring access to life-changing and life-saving medications is not just a commitment, it’s our responsibility.
More than 54,300+ employees globally serve over 130 markets to build a healthier, more sustainable tomorrow.
Our Businesses
Pioneering scientific breakthroughs for both human and animal health, the U.S. is the largest subsidiary of Boehringer Ingelheim, serving more than 10 million patients annually.
[Read more](/content/us/about-us/who-we-are/our-businesses "Teaser headline Our Businesses"/index.html)
Our promise to our people
How we live up to our evolved employer value proposition.
[2022 Rising Star Leads with Fearless Determination](/content/us/about-us/who-we-are/rising-star-leads-determination-boehringer-ingelheim-us "Rising Star Leads with Determination | Boehringer Ingelheim US"/index.html)